Somri Gannam L, Meisel Sharon S, Hantisteanu S, Bar Noy T, Sigal E, Groisman G, et al. IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancer. Front Oncol. 2024;14:1410447 pubmed publisher

Hamdan F, Feodoroff M, Russo S, Fusciello M, Feola S, Chiaro J, et al. Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses. Mol Ther Oncolytics. 2023;28:264-276 pubmed publisher

Moreno Fernandez M, Damen M, Divanovic S. A protocol for isolation of primary human immune cells from the liver and mesenteric white adipose tissue biopsies. STAR Protoc. 2021;2:100937 pubmed publisher

Hamdan F, Ylösmäki E, Chiaro J, Giannoula Y, Long M, Fusciello M, et al. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. J Immunother Cancer. 2021;9: pubmed publisher

Walter F, Winter E, Rahn S, Heidland J, Meier S, Struzek A, et al. Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses. PLoS ONE. 2020;15:e0239369 pubmed publisher